Sonoma Pharmaceuticals (SNOA) Receivables (2011 - 2025)

Sonoma Pharmaceuticals' Receivables history runs 15 years deep, the most recent figure standing at $2.4 million for Q4 2025.

• In Q4 2025, Receivables fell 0.96% year-over-year to $2.4 million; the TTM figure through Dec 2025 stood at $2.4 million (down 0.96% YoY), while the FY2025 annual figure was $2.2 million, down 23.42% from the prior year.
• Receivables was $2.4 million for Q4 2025 at Sonoma Pharmaceuticals, down from $2.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.4 million in Q3 2021 to a low of $2.2 million in Q3 2023.
• Historically, Receivables has averaged $2.7 million across 5 years, with a median of $2.6 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Receivables tumbled 37.2% in 2021, then jumped 42.02% in 2024.
• A 5-year view of Receivables shows it stood at $2.9 million in 2021, then slipped by 19.52% to $2.3 million in 2022, then grew by 25.21% to $2.9 million in 2023, then declined by 16.38% to $2.4 million in 2024, then fell by 0.96% to $2.4 million in 2025.
• The last three Receivables figures came in at $2.4 million (Q4 2025), $2.7 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.